Diffusion Pharmaceuticals, Inc. (DFFN)

NASDAQ: DFFN · IEX Real-Time Price · USD
6.91
-0.22 (-3.09%)
At close: Jun 24, 2022 4:00 PM
6.92
+0.01 (0.14%)
After-hours: Jun 24, 2022 4:28 PM EDT
-3.09%
Market Cap 14.09M
Revenue (ttm) n/a
Net Income (ttm) -23.98M
Shares Out 2.04M
EPS (ttm) -11.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 28,779
Open 7.08
Previous Close 7.13
Day's Range 6.91 - 7.24
52-Week Range 5.10 - 43.00
Beta 1.64
Analysts Sell
Price Target 40.80 (+490.4%)
Earnings Date Aug 10, 2022

About DFFN

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia. [Read more...]

Industry Biotechnology
Founded 2001
Employees 16
Stock Exchange NASDAQ
Ticker Symbol DFFN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for DFFN stock is "Sell." The 12-month stock price forecast is 40.8, which is an increase of 490.45% from the latest price.

Price Target
$40.8
(490.45% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

CHARLOTTESVILLE, Va., June 23, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing therapies that enhance the bod...

Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer

Appointment brings 20 years of regulatory affairs experience and exceptional leadership capabilities Appointment brings 20 years of regulatory affairs experience and exceptional leadership capabilities

Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

CHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance t...

Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements

CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance t...

5 Stocks Halted In Tuesday's Session

A circuit breaker is an automatic, temporary trading halt on specific securities when the underlying stock is experiencing times of high volatility. It is a measure to help restore and bring order to th...

Other symbols: LGHLSBFMSEVTHCA

Diffusion Pharmaceuticals' 50-For-1 Stock Split Will Go Into Effect Tomorrow

Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) will effect a 1-for-50 reverse stock split of its common stock.  The reverse stock split is expected to become effective and commence trading on a post-split...

Why Diffusion Pharmaceuticals Shares Are Falling

Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) shares are trading lower by 20.83% at $0.21 after the company announced a 1-for-50 reverse stock split. Diffusion Pharmaceuticals says the reverse stock spli...

Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan

Split Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022 Split Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022

Diffusion Pharmaceuticals Completes Dosing in Altitude Trial

Topline data expected within two months

Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders

• Special Meeting of Stockholders Rescheduled to Monday, April 18, 2022 at 9:00 a.m. E.T. • No Change to Meeting Location, Record Date, or Proposals to Be Voted Upon

Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update

CHARLOTTESVILLE, Va., March 21, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies ...

Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical On...

New SAB Members Bring Expertise in the Fields of Radiation Biology and Tumor Hypoxia New SAB Members Bring Expertise in the Fields of Radiation Biology and Tumor Hypoxia

Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnerin...

CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc . (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance...

Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial

Third of Three TSC Oxygenation Trials Third of Three TSC Oxygenation Trials

Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523

Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer

Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility

Check these three biotech penny stocks out for your list this month The post Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility appeared first on Penny Stocks to Buy, Picks, News and In...

Other symbols: IBIOLPTX

Diffusion Pharmaceuticals Doses First Participants in Altitude Trial

Second of Three TSC Oxygenation Trials Second of Three TSC Oxygenation Trials

Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

CHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance ...

Diffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma Conference

CHARLOTTESVILLE, Va., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies t...

7 Biotech Penny Stocks With Huge Catalysts Coming in 2022

With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market. The post 7 Biotech Penny Stocks With Huge Catalysts Coming in 2022 appe...

Other symbols: ATRXBLUCYDYENTX

Diffusion Pharmaceuticals Issues Letter to Shareholders

CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies ...

Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference

Conference to Take Place Virtually, September 13-15, 2021 Conference to Take Place Virtually, September 13-15, 2021

Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA's Pulmonology, Allergy, and Critical ...

Phase 2 DLCO Trial in Interstitial Lung Disease Expected to Begin in Q4 Under New IND

Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update

CHARLOTTESVILLE, Va., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies t...

Making a List of Penny Stocks to Buy? Here's 7 to Watch in Summer 2021

Does your list of penny stocks to watch include these 7 hot small-caps? The post Making a List of Penny Stocks to Buy?

Other symbols: BBIGCTXRPBTSSHIPVVOS